No Data
Baike Biotech: Announcement on the 2024 Annual Results Forecast of Changchun Baike Biotechnology Co., Ltd.
Announcement of the 2024 annual results forecast of Changchun Baike Biotechnology Co., Ltd.
Baike Biological (688276.SH): The net income for 2024 is expected to decrease by 52.10% to 60.08%.
On January 23, Gelonghui reported that Baike Biotechnology (688276.SH) released its annual performance forecast for 2024, estimating that the net income attributable to the owners of the parent company will be between 200 million yuan and 240 million yuan, a year-on-year decrease of 52.10% to 60.08%. It is expected that the net income attributable to the owners of the parent company, excluding non-recurring gains and losses, will be between 197.79 million yuan and 237.79 million yuan, a year-on-year decrease of 51.80% to 59.91%. During the reporting period, the public's willingness to get vaccinated.
Shareholder Wei Xue Ning has cumulatively reduced his shareholding by 0.3018 million shares in Baike Biology (688276.SH).
Baike Biological (688276.SH) announced that on January 15, 2025, the company received a shareholding notification from Shareholder Wei Xue Ning...
Bai Ke Biological (688276.SH): Application for clinical trials of type II herpes simplex virus mRNA vaccine has been approved.
On December 20, Gelonghui announced that Baike Biomedical (688276.SH) recently received the "Notice of Approval for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration, agreeing to conduct clinical trials for the prevention of genital herpes caused by type II herpes simplex virus infection. Genital herpes caused by type II herpes simplex virus infection is a contagious disease primarily spread through sexual activity, which is easily transmitted, recurrent, and lacks effective curative measures, leading to a serious public health issue. To prevent the occurrence of genital herpes, multiple Biomedical companies have been continuously working on the research and development of herpes simplex virus vaccines.
Baikexing Biological (688276.SH) no longer recognizes Zhu Changlin as a core technical personnel.
Baike Biological (688276.SH) released an announcement that the company, based on its Global Strategy development plan, comprehensively considers the company's research and development projects...
Investors Still Waiting For A Pull Back In Changchun BCHT Biotechnology Co. (SHSE:688276)